Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
暂无分享,去创建一个
E. B. Butler | M. Kattan | C. Roehrborn | P. Scardino | M. Zelefsky | E. Klein | S. Shariat | S. Leibel | P. Kupelian | A. Stephenson | K. Slawin | S. Liauw | B. Teh | M. Katz | D. Pistenmaa | H. Pacholke | E. Butler
[1] Victor Reuter,et al. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. , 2003, The Journal of urology.
[2] C. Roehrborn,et al. Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. , 2003, Urology.
[3] Patrick W McLaughlin,et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] E. Venkatraman,et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Renshaw,et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Juni Palmgren,et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2002, The New England journal of medicine.
[7] D. Song,et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. , 2002, Urology.
[8] Michael J. Zelefsky,et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. , 2002, International journal of radiation oncology, biology, physics.
[9] A. Zietman,et al. Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors. , 2002, Urology.
[10] Michael W Kattan,et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. , 2002, The Journal of urology.
[11] A. Partin,et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.
[12] P. Carroll,et al. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? , 2001, The Journal of urology.
[13] E. Bergstralh,et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. , 2001, Mayo Clinic proceedings.
[14] S. Shariat,et al. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. , 2001, Radiology.
[15] D. Hussey. American Society for Therapeutic Radiology and Oncology , 2001 .
[16] E. Bergstralh,et al. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? , 2001, The Journal of urology.
[17] E. B. Butler,et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Moul. Prostate specific antigen only progression of prostate cancer. , 2000, The Journal of urology.
[19] D W Hillman,et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. , 2000, The Journal of urology.
[20] D. Chan,et al. Natural History of Progression After PSA Elevation Following Radical Prostatectomy , 1999 .
[21] C. Ling,et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. , 1999, International journal of radiation oncology, biology, physics.
[22] D. Kuban,et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. , 1999, JAMA.
[23] P. Schellhammer,et al. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Valicenti,et al. Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: the importance of radiation dose. , 1998, Urology.
[25] M. Toublanc,et al. Adjuvant radiation therapy for recurrent PSA after radical prostatectomy in T1–T2 prostate cancer , 1998, Prostate Cancer and Prostatic Diseases.
[26] D. Ornstein,et al. Evaluation and management of men whose radical prostatectomies failed: results of an international survey. , 1998, Urology.
[27] P. Carroll,et al. Radiation therapy for the management of biopsy proved local recurrence after radical prostatectomy. , 1998, The Journal of urology.
[28] P. Carroll,et al. Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database. , 1998, The Journal of urology.
[29] M. Banerjee,et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. , 1998, The Journal of urology.
[30] M. Soloway,et al. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. , 1998, The Journal of urology.
[31] M. Bagshaw. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer , 1998, International journal of radiation oncology, biology, physics.
[32] J. Dekernion,et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. , 1997, The Journal of urology.
[33] T. Stamey,et al. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. , 1997, Urology.
[34] J. Forman,et al. Predicting the need for adjuvant systemic therapy in patients receiving postprostatectomy irradiation. , 1996, Urology.
[35] G. Montana,et al. The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. , 1995, International journal of radiation oncology, biology, physics.
[36] J. Oesterling,et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.
[37] A. Partin,et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. , 1994, Urology.
[38] P. Lange,et al. Prostate specific antigen and local recurrence after radical prostatectomy. , 1990, The Journal of urology.
[39] D. Kuban,et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] M S Anscher,et al. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. , 2000, International journal of radiation oncology, biology, physics.
[41] J. Cadeddu,et al. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. , 1998, The Journal of urology.